Expression of a soluble TGF-β receptor by tumor cells enhances dendritic cell/tumor fusion vaccine efficacy

Journal of Immunology

Volumn 181, Issue 5, 2008, Pages 3690-3697

  Zhang, Min ^a   Berndt, Bradford E ^a   Chen, Jian Jun ^a   Kao, John Y ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BETA GALACTOSIDASE; FC RECEPTOR; IMMUNOGLOBULIN M; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TUMOR VACCINE; CANCER VACCINE; TUMOR ANTIGEN;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER IMMUNIZATION; CARCINOMA CELL; CELL ASSAY; CELL ISOLATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; GENETIC TRANSFECTION; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TUMOR IMMUNITY; VIRAL GENE DELIVERY SYSTEM; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DENDRITIC CELL; GENETICS; HUMAN; METABOLISM; NEOPLASM; PATHOLOGY; TRANSPLANTATION; TUMOR CELL LINE;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL LINE, TUMOR; DENDRITIC CELLS; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; NEOPLASMS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; T-LYMPHOCYTES, REGULATORY; TRANSFECTION;

EID: 51549090632     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.181.5.3690     Document Type: Article

References (32)

1. Hsu, F. J., C. Benike, F. Fagnoni, T. M. Liles, D. Czerwinski, B. Taidi, E. G. Engleman, and R. Levy. 1996. Vaccination of patients with B-cell lymphoma using autologous antigen- pulsed dendritic cells. Nat. Med. 2: 52-58.
2. Kugler, A., G. Stuhler, P. Walden, G. Zoller, A. Zobywalski, P. Brossart, U. Trefzer, S. Ullrich, C. A. Muller, V. Becker, et al. 2000. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat. Med. 6: 332-336. (Pubitemid 30148627)
3. Murphy, G. P., B. A. Tjoa, S. J. Simmons, J. Jarisch, V. A. Bowes, H. Ragde, M. Rogers, A. Elgamal, G. M. Kenny, O. E. Cobb, et al. 1999. Infusion of dendritic cells pulsed with HLA-A2-specific prostate- specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate 38: 73-78.
4. Nestle, F. O., S. Alijagic, M. Gilliet, Y. Sun, S. Grabbe, R. Dummer, G. Burg, and D. Schadendorf. 1998. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4: 328-332. (Pubitemid 28144092)
5. Tjoa, B. A., P. A. Lodge, M. L. Salgaller, A. L. Boynton, and G. P. Murphy. 1999. Dendritic cell-based immunotherapy for prostate cancer. CA Cancer J. Clin. 49: 117-128: 165.
6. Berzofsky, J. A., M. Terabe, S. Oh, I. M. Belyakov, J. D. Ahlers, J. E. Janik, and J. C. Morris. 2004. Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J. Clin. Invest. 113: 1515-1525. (Pubitemid 39071672)
7. Kao, J. Y., Y. Gong, C. M. Chen, Q. D. Zheng, and J. J. Chen. 2003. Tumorderived TGF-β reduces the efficacy of dendritic cell/tumor fusion vaccine. J. Immunol. 170: 3806-3811.
8. Kao, J. Y., M. Zhang, C. M. Chen, A. Pierzchala, and J. J. Chen. 2006. Aberrant T helper cell response in tumor-bearing mice limits the efficacy of dendritic cell vaccine. Immunol. Lett. 105: 16-25.
9. Juang, C. M., C. F. Hung, J. Y. Yeh, H. C. Horng, N. F. Twu, M. H. Cheng, K. C. Wen, C. C. Yuan, K. C. Chao, T. C. Wu, and M. S. Yen. 2007. Regulatory T cells: potential target in anticancer immunotherapy. Taiwan J. Obstet. Gynecol. 46: 215-221. (Pubitemid 47572280)
10. Fearon, E. R., and B. Vogelstein. 1990. A genetic model for colorectal tumorigenesis. Cell 61: 759-767.
11. DeMatos, P., Z. Abdel-Wahab, C. Vervaert, and H. F. Seigler. 1998. Vaccination with dendritic cells inhibits the growth of hepatic metastases in B6 mice. Cell. Immunol. 185: 65-74. (Pubitemid 28272676)
12. Chen, J. J., Y. Sun, and G. J. Nabel. 1998. Regulation of the proinflammatory effects of Fas ligand (CD95L). Science 282: 1714-1717. (Pubitemid 28549288)
13. Warger, T., P. Osterloh, G. Rechtsteiner, M. Fassbender, V. Heib, B. Schmid, E. Schmitt, H. Schild, and M. P. Radsak. 2006. Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo. Blood 108: 544-550. (Pubitemid 44061354)
14. Lapteva, N., M. R. Seethammagari, B. A. Hanks, J. Jiang, J. M. Levitt, K. M. Slawin, and D. M. Spencer. 2007. Enhanced activation of human dendritic cells by inducible CD40 and Toll-like receptor-4 ligation. Cancer Res. 67: 10528-10537. (Pubitemid 350070829)
15. + regulatory T cells from peripheral Foxp3- precursors. Blood 110: 4293-4302.
16. + T cells. J. Immunol. 155: 609-618.
17. Fujita, S., K. Seino, K. Sato, Y. Sato, K. Eizumi, N. Yamashita, and M. Taniguchi. 2006. Regulatory dendritic cells act as regulators of acute lethal systemic inflammatory response. Blood 107: 3656-3664.
18. Rutella, S., S. Danese, and G. Leone. 2006. Tolerogenic dendritic cells: cytokine modulation comes of age. Blood 108: 1435-1440. (Pubitemid 44316106)
19. Bollard, C. M., C. Rossig, M. J. Calonge, M. H. Huls, H. J. Wagner, J. Massague, M. K. Brenner, H. E. Heslop, and C. M. Rooney. 2002. Adapting a transforming growth factor β-related tumor protection strategy to enhance antitumor immunity. Blood 99: 3179-3187.
20. Shah, A. H., W. B. Tabayoyong, S. D. Kundu, S. J. Kim, L. Van Parijs, V. C. Liu, E. Kwon, N. M. Greenberg, and C. Lee. 2002. Suppression of tumor metastasis by blockade of transforming growth factor β signaling in bone marrow cells through a retroviral-mediated gene therapy in mice. Cancer Res. 62: 7135-7138.
21. Zhang, F., J. Lee, S. Lu, C. A. Pettaway, and Z. Dong. 2005. Blockade of transforming growth factor-β signaling suppresses progression of androgen-independent human prostate cancer in nude mice. Clin. Cancer Res. 11: 4512-4520. (Pubitemid 40825642)
22. Wu, R. S., J. J. Kobie, D. G. Besselsen, T. C. Fong, V. D. Mack, J. A. McEarchern, and E. T. Akporiaye. 2001. Comparative analysis of IFN-γ B7.1 and antisense TGF-β gene transfer on the tumorigenicity of a poorly immunogenic metastatic mammary carcinoma. Cancer Immunol. Immunother. 50: 229-240.
23. McEarchern, J. A., J. J. Kobie, V. Mack, R. S. Wu, L. Meade-Tollin, C. L. Arteaga, N. Dumont, D. Besselsen, E. Seftor, M. J. Hendrix, et al. 2001. Invasion and metastasis of a mammary tumor involves TGF-β signaling. Int. J. Cancer 91: 76-82.
24. Muraoka, R. S., N. Dumont, C. A. Ritter, T. C. Dugger, D. M. Brantley, J. Chen, E. Easterly, L. R. Roebuck, S. Ryan, P. J. Gotwals, et al. 2002. Blockade of TGF-β inhibits mammary tumor cell viability, migration, and metastases. J. Clin. Invest. 109: 1551-1559.
25. Kobie, J. J., R. S. Wu, R. A. Kurt, S. Lou, M. K. Adelman, L. J. Whitesell, L. V. Ramanathapuram, C. L. Arteaga, and E. T. Akporiaye. 2003. Transforming growth factor β inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines. Cancer Res. 63: 1860-1864.
26. Hewitt, H. B., E. R. Blake, and A. S. Walder. 1976. A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin. Br. J. Cancer 33: 241-259.
27. Kao, J. Y., M. Zhang, C. M. Chen, and J. J. Chen. 2005. Superior efficacy of dendritic cell-tumor fusion vaccine compared with tumor lysate-pulsed dendritic cell vaccine in colon cancer. Immunol. Lett. 101: 154-159.
28. Seiler, M. P., S. Gottschalk, V. Cerullo, M. Ratnayake, V. P. Mane, C. Clarke, D. J. Palmer, P. Ng, C. M. Rooney, and B. Lee. 2007. Dendritic cell function after gene transfer with adenovirus-calcium phosphate co-precipitates. Mol. Ther. 15: 386-392. (Pubitemid 46111890)
29. Pereboev, A. V., J. M. Nagle, M. A. Shakhmatov, P. L. Triozzi, Q. L. Matthews, Y. Kawakami, D. T. Curiel, and J. L. Blackwell. 2004. Enhanced gene transfer to mouse dendritic cells using adenoviral vectors coated with a novel adapter molecule. Mol. Ther. 9: 712-720.
30. Wahl, S. M., J. Wen, and N. Moutsopoulos. 2006. TGF-β: a mobile purveyor of immune privilege. Immunol. Rev. 213: 213-227.
31. Kaiga, T., M. Sato, H. Kaneda, Y. Iwakura, T. Takayama, and H. Tahara. 2007. Systemic administration of IL-23 induces potent antitumor immunity primarily mediated through Th1-type response in association with the endogenously expressed IL-12. J. Immunol. 178: 7571-7580. (Pubitemid 46898026)
32. Kryczek, I., S. Wei, L. Zou, S. Altuwaijri, W. Szeliga, J. Kolls, A. Chang, and W. Zou. 2007. Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J. Immunol. 178: 6730-6733. (Pubitemid 46847396)